In this issue:
Analysis of ER/PR/HER2 subtypes, treatment and outcomes
30-day mortality after systemic anticancer therapy
Adding veliparib + carboplatin to standard AC-paclitaxel in TNBC
FDA analysis of bone-only metastatic breast cancer
Lung cancer more common in young US women vs men
Neoadjuvant nivolumab in resectable lung cancer
Immune-related AEs with PD1 and PDL1 inhibitors
Adjuvant chemotherapy: 3 vs 6 months in stage III colon cancer
cfDNA predicts treatment failure in locally advanced rectal cancer
S-1, irinotecan + bevacizumab for first-line metastatic CRC therapy?
Please login below to download this issue (PDF)